JKS - EOG HEXO among premarket losers
scPharmaceuticals (SCPH) -40% on complete response letter from FDA for FUROSCIX.Lyra Therapeutics, Inc. (LYRA) -28% on positive topline results for LANTERN phase 2 randomized controlled study of LYR-210 for the treatment of chronic rhinosinusitis with and without nasal polyps.Aptose Biosciences Inc. (APTO) -28% on highlights from ASH and corporate update event.Nano Dimension NNDM -15% on pricing $180M direct offering.China HGS Real Estate (HGSH) -14%.Bellicum Pharmaceuticals BLCM -11% as clinical hold placed on BPX-601 phase 1/2 clinical trial.Globus Maritime Limited GLBS -12% on Q3 results.NanoVibronix, Inc. (NAOV) -10%.Fangdd Network (DUO) -10%.Trillium Therapeutics (TRIL) -10%.China Automotive Systems (CAAS) -9%.Aemetis (AMTX) -9%.Iconix Brand (ICON) -9%.Pioneer Power Solutions (PPSI) -8%.XPeng Inc. (XPEV) -8%. on filing for capital raise.HEXO Corp. (HEXO) -7%.Hexindai Inc. (HX) -7%.Lordstown Motors (RIDE) -8% as S-1 registration statement declared effective.Orbital Energy Group, Inc. (OEG) -7%.Nesco Holdings, Inc. (NSCO) -6%.Foresight Autonomous Holdings Ltd. (FRSX) -6%.Star Peak Energy Transition Corp. (STPK) -7%.JinkoSolar Holding Co., Ltd. (JKS) -6% on Q3 results.India Globalization Capital, Inc. (IGC) -6%.EOG
For further details see:
EOG, HEXO among premarket losers